Beta-adrenergic blocking drugs in severe heart failure

Reviews in Cardiovascular Medicine

Volumn 3, Issue SUPPL. 3, 2002, Pages

  Fowler, Michael ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Beta adrenergic blocking drugs; Heart failure; Norepinephrine; Sympathetic nervous system

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; METOPROLOL SUCCINATE; MOXONIDINE; PROPRANOLOL; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; HEART FAILURE; HEART HEMODYNAMICS; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MORTALITY; PROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL; WELLBEING;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS; SURVIVAL RATE; SYMPATHETIC NERVOUS SYSTEM;

EID: 0036382035     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Cannon WB. Bodily Changes in Pain, Hunger, Fear, and Rage. Boston: Branford; 1929.
2. Chidsey CA, Braunwald E, Marrow AG. Catecholamine excretion and cardiac stress of norepinephrine in congestive heart failure. Am J Med. 1965;39:442-451.
3. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205-211.
4. Fowler MB, Laser JA, Hopkins GL, et al. Assessment of the β-adrenergic receptor pathway in the intact failing heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation. 1986;74:1290-1302.
5. Swedberg K, Chatterjee K, Roizen M, et al. Myocardial norepinephrine release in congestive heart failure. Circulation. 1982;66:11-23.
6. Packer M, Coats A, Fowler MB, et al, for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
7. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94:2817-2825.
8. Swedberg K, Bristow MR, Cohn JN, et al. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation. 2002;105:1797-1803.
9. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet. 1999;353:9-13.
10. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
11. Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 1994;89:1632-1642.
12. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
13. Goldstein S, Fagerberg B, Hjalmarson A, et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol. 2001;38:932-938.
14. Rose EA, Gelijns AC, Moskowitz AJ, et al.. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345:1435-1443.
15. Packer M, Bristow MR, Cohn JN, et al, for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.